2:24 PM
May 11, 2017
 |  BC Innovations  |  Translation in Brief

Going universal

Celyad kicks antigen specificity out of the CAR

Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD) is going allogeneic and ditching antigen specificity to broaden the reach of its chimeric antigen receptor (CAR)-expressing T cells. By suppressing endogenous T cell receptor (TCR) expression and using NK cell stress detectors instead of antigen receptors in its CARs, the company hopes to create individual products that can be used off-the-shelf to kill a wide range of solid and hematological cancers.

Formerly Cardio3 BioSciences S.A., Celyad began developing cancer immunotherapies after acquiring Celdara Medical LLC’s oncology division in 2015.

The deal gave Celyad an autologous NK cell receptor-based CAR T cell platform. Because NK cell receptors react to a variety of signals expressed on the surfaces of stressed cells, unlike traditional CAR T cells that express receptors against specific tumor antigens, the company expects its therapies to be broadly applicable to a range of tumor types.

The company’s lead candidate, CAR-T NKR-2, comprises autologous T cells...

Read the full 763 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >